29.45USD+3.84%Mkt Cap: 1.35B USDP/E: —Last update: 2026-05-26
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.35B USD
Enterprise Value934.20M USD
Revenue (TTM)72.25M USD
Gross Profit72.25M USD
Net Income (TTM)-48.88M USD
Revenue/Share1.625 USD
Last Price29.45 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees130
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-10.28
PEG—
EV/EBITDA-14.04
EV/Revenue12.93
P/S17.42
P/B3.28
EPS (TTM)-0.80
EPS (Forward)-2.72
52W Range
9.04587% of range32.63
52W High32.63 USD
52W Low9.045 USD
Profitability
Gross Margin100.00%
Oper. Margin-50.14%
EBITDA Margin-92.12%
Profit Margin-106.37%
ROE-12.80%
ROA-8.20%
Growth
Revenue Growth12011.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF110.19M USD
CapEx (TTM)518.00K USD
FCF Margin33.24%
FCF Yield1.77%
Net Debt-324.31M USD
Net Debt/EBITDA4.87
Balance Sheet
Debt/Equity0.06
Current Ratio4.71
Quick Ratio4.63
Book Value/Sh8.524 USD
Cash/Share7.707 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)44.25 USD
Target Range35.00 USD – 60.00 USD
# Analysts8
Ownership
Shares Out.45.08M
Float23.12M
Insiders3.09%
Institutions102.61%
Short Interest
Short Ratio6.1d
Short % Float9.11%
Short % Out.4.60%
Shares Short2.07M
Short (prev mo.)2.18M
Technical
SMA 5024.90 (+18.3%)
SMA 20022.85 (+28.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)350.70K
Avg Vol (10d)333.74K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—